TITLE

Pharmacological Characterization of Memoquin, a Multi-Target Compound for the Treatment of Alzheimer's Disease

AUTHOR(S)
Capurro, Valeria; Busquet, Perrine; Lopes, Joao Pedro; Bertorelli, Rosalia; Tarozzo, Glauco; Bolognesi, Maria Laura; Piomelli, Daniele; Reggiani, Angelo; Cavalli, Andrea
PUB. DATE
February 2013
SOURCE
PLoS ONE;Feb2013, Vol. 8 Issue 2, p1
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Alzheimer's disease (AD) is characterized by progressive loss of cognitive function, dementia and altered behavior. Over 30 million people worldwide suffer from AD and available therapies are still palliative rather than curative. Recently, Memoquin (MQ), a quinone-bearing polyamine compound, has emerged as a promising anti-AD lead candidate, mainly thanks to its multi-target profile. MQ acts as an acetylcholinesterase and β-secretase-1 inhibitor, and also possesses anti-amyloid and anti-oxidant properties. Despite this potential interest, in vivo behavioral studies with MQ have been limited. Here, we report on in vivo studies with MQ (acute and sub-chronic treatments; 7–15 mg/kg per os) carried out using two different mouse models: i) scopolamine- and ii) beta-amyloid peptide- (Aβ-) induced amnesia. Several aspects related to memory were examined using the T-maze, the Morris water maze, the novel object recognition, and the passive avoidance tasks. At the dose of 15 mg/kg, MQ was able to rescue all tested aspects of cognitive impairment including spatial, episodic, aversive, short and long-term memory in both scopolamine- and Aβ-induced amnesia models. Furthermore, when tested in primary cortical neurons, MQ was able to fully prevent the Aβ-induced neurotoxicity mediated by oxidative stress. The results support the effectiveness of MQ as a cognitive enhancer, and highlight the value of a multi-target strategy to address the complex nature of cognitive dysfunction in AD.
ACCESSION #
87625004

 

Related Articles

  • A Novel Application of Multiscale Entropy in Electroencephalography to Predict the Efficacy of Acetylcholinesterase Inhibitor in Alzheimer’s Disease. Tsai, Ping-Huang; Chang, Shih-Chieh; Liu, Fang-Chun; Tsao, Jenho; Wang, Yung-Hung; Lo, Men-Tzung // Computational & Mathematical Methods in Medicine;5/18/2015, Vol. 2015, p1 

    Alzheimer’s disease (AD) is the most common form of dementia. According to one hypothesis, AD is caused by the reduced synthesis of the neurotransmitter acetylcholine. Therefore, acetylcholinesterase (AChE) inhibitors are considered to be an effective therapy. For clinicians, however,...

  • Prophylactic melatonin significantly reduces Alzheimer's neuropathology and associated cognitive deficits independent of antioxidant pathways in AβPPswe/PS1 mice. O'Neal-Moffitt, G.; Delic, V.; Bradshaw, P. C.; Olcese, J. // Molecular Neurodegeneration;Jul2015, Vol. 10 Issue 1, p1 

    Background: Alzheimer's disease (AD) underlies dementia for millions of people worldwide, and its occurrence is set to double in the next 20 years. Currently, approved drugs for treating AD only marginally ameliorate cognitive deficits, and provide limited symptomatic relief, while newer...

  • Screening of Pancratium maritimum L. for acetylcholinesterase inhibitory alkaloids using thin layer chromatography in combination with bioactivity staining. Abou-Donia, Amina H.; Shawky, Eman; Mohy El-Din, Mohamed M.; Seif El Din, Ahmed A. // Journal of Natural Pharmaceuticals;Jan-Jun2013, Vol. 4 Issue 1, p61 

    Background: Inhibition of acetylcholinesterase (AChE), the key enzyme in the breakdown of acetylcholine, is considered as a promising strategy for the treatment of neurological disorders such as Alzheimer's disease, senile dementia, ataxia, and myasthenia gravis. A potential source of AChE...

  • Neuroprotective effects of donepezil against cholinergic depletion. Cutuli, Debora; Bartolo, Paola De; Caporali, Paola; Tartaglione, Anna Maria; Oddi, Diego; D'Amato, Francesca Romana; Nobili, Annalisa; D'Amelio, Marcello; Petrosini, Laura // Alzheimer's Research & Therapy;2013, Vol. 5 Issue 5, p2 

    Introduction Intraparenchymal injections of the immunotoxin 192-IgG-saporin into medial septum and nucleus basalis magnocellularis causes a selective depletion of basal forebrain cholinergic neurons. Thus, it represents a valid model to mimic a key component of the cognitive deficits associated...

  • Cholinesterase inhibitors from botanicals. Ahmed, Faiyaz; Murad Ghalib, Raza; Sasikala, P.; Mueen Ahmed, K. K. // Pharmacognosy Reviews;Jul-Dec2013, Vol. 7 Issue 14, p121 

    Alzheimer's disease (AD) is a progressive neurodegenerative disease, wherein a progressive loss of cholinergic synapses occurs in hippocampus and neocortex. Decreased concentration of the neurotransmitter, acetylcholine (ACh), appears to be critical element in the development of dementia, and...

  • Alzheimer's disease Inhibitors: Current status and future prospects. Singh, Ankit // International Journal of Pharmacy & Life Sciences;Aug2014, Vol. 5 Issue 8, p3734 

    Alzheimer disease is a major public health problem in the elderly. It is the most predominant, intricate neurodegenerative disorder of the brain, affecting above 20 million individuals global. It is an insanity related disease which is characterized by t-protein aggregation, amyloid- β...

  • Clinical Profile of PiB-Positive Corticobasal Syndrome. Burrell, James R.; Hornberger, Michael; Villemagne, Victor L.; Rowe, Christopher C.; Hodges, John R. // PLoS ONE;Apr2013, Vol. 8 Issue 4, p1 

    Background: Corticobasal syndrome (CBS) is a multifaceted neurodegenerative disorder characterized by a combination of motor and cognitive deficits. Several different pathological entities, including Alzheimer’s pathology, have been described in association with CBS. The present study...

  • Timosaponin B-II ameliorates scopolamine-induced cognition deficits by attenuating acetylcholinesterase activity and brain oxidative damage in mice. Zhao, Xu; Liu, Chunmei; Qi, Yu; Fang, Lina; Luo, Jie; Bi, Kaishun; Jia, Ying // Metabolic Brain Disease;Dec2016, Vol. 31 Issue 6, p1455 

    Timosaponin B-II (TB-II) is a main active saponin isolated from the rhizome of Anemarrhena asphodeloides Bge., which is widely used in traditional Chinese medicine. In this study, the effect of TB-II on learning and memory was investigated in a scopolamine-induced mouse model of Alzheimer's...

  • The Impact of Neuropsychological Deficits on Functional Stroke Outcomes. Barker-Collo, Suzanne; Feigin, Valery // Neuropsychology Review;Jun2006, Vol. 16 Issue 2, p53 

    This review examines the available literature on neuropsychological outcomes of stroke and the literature on the ability of specific areas of neuropsychological deficit to predict functional stroke outcome. The literature reviewed indicates that post-stroke deficits in executive function,...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics